Special Feature New strategy for HER-2 testing and trastuzumab therapy

Breast Cancer

, Volume 16, Issue 4, pp 295-300

The role of trastuzumab in the management of HER2-positive metastatic breast cancer: an updated review

  • Yutaka TokudaAffiliated withDepartment of Breast and Endocrine Surgery, Tokai University School of Medicine Email author 
  • , Yasuhiro SuzukiAffiliated withDepartment of Breast and Endocrine Surgery, Tokai University School of Medicine
  • , Yuki SaitoAffiliated withDepartment of Breast and Endocrine Surgery, Tokai University School of Medicine
  • , Shinobu UmemuraAffiliated withDepartment of Pathology, Tokai University School of Medicine

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Currently, trastuzumab is one of the key drugs in the treatment strategy for HER2-positive breast cancer. Although metastatic breast cancer is unlikely to be cured, some HER2-positive patients have survived for a long time with complete response to trastuzumab therapy. In HER2-positive metastatic breast cancer, single agent trastuzumab is effective and less toxic. Combination of trastuzumab with cytotoxic drugs is also effective. Therefore, major guidelines recommend using trastuzumab as a key drug in the management of HER2-positive metastatic breast cancer. However, many clinical questions still need to be solved. In this article, recent evidence was reviewed to find some answers about these issues.

Keywords

Metastatic breast cancer HER2-positive Trastuzumab